Table 1. Characteristics of 322 patients from whom serum samples were tested for BDG measurementa.
| Value for patients with: | ||||
|---|---|---|---|---|
| IA (n = 40) | IC (n = 78) | PJP (n = 17) | No IFD (n = 187) | |
| Median (interquartile range) age, years | 53.0 (38.7–60.2) | 52.5 (40.2–60.0) | 52.0 (33.0–64.0) | 54.0 (42.0–68.0) |
| Sex, male/female | 18/22 | 34/44 | 7/10 | 90/97 |
| Underlying condition, no. of patients (%) | ||||
| Abdominal surgery | 0 (0.0) | 6 (7.7) | 0 (0.0) | 15 (8.0) |
| Solid tumor | 9 (22.5) | 22 (28.2) | 2 (11.8) | 23 (12.3) |
| Haematologic malignancy/HSCT | 23 (57.5) | 2 (2.6) | 7 (41.2) | 92 (49.2) |
| Otherb | 8 (20.0) | 48 (61.5) | 8 (47.0) | 57 (30.5) |
BDG, 1,3-β-D-glucan; IA, invasive aspergillosis; IC, invasive candidiasis; PJP, Pneumocystis jirovecii pneumonia; IFD, invasive fungal disease; HSCT, hematopoietic stem cell transplantation.
a BDG testing was performed in parallel with the Fungitell assay (FA) and the Wako β-glucan test (GT).
b Includes patients in intensive care and infectious disease units.